From Biomarker Discovery to Clinical Use: The important steps to Translate Research to Clinical Practice

Translating a biomarker discovery project into actionable outcomes in clinical practice is a challenging endeavor that demands a holistic approach encompassing both rigorous scientific research and a well-thought-out business strategy. At Protavio, our team of researchers and project managers have hands-on experience with over 150 biomarker projects, collaborating with diverse entities ranging from academic institutions, startup teams, SMEs, as well as large multinational corporations. This breadth of experience gives us a unique vantage point, allowing us to understand the important points to bridge the chasm that often exists between pure academic research and the commercialization of healthcare technologies.

While traditional academic measures like paper citations and h-index scores are important, they often don’t tell the full story. The real impact of research lies in its translational potential—its ability to transform healthcare practices and improve patient outcomes. It’s surprising for many to learn that even a set of biomarkers with exceptional clinical performance may face numerous hurdles before it can be successfully deployed in a clinical setting. Several crucial elements must be meticulously addressed for a biomarker project to realize its full commercial and clinical potential. Here’s a rundown:

  • Commercialization Plan: A roadmap is essential for defining the target market, market penetration strategies, and potential partnerships.
  • Platform Selection: The choice of technology for biomarker detection and quantification can make or break the project. Equipment cost, deployment potential, maintenance, automation capabilities, random access capabilities, multiplexability, LIMS integration, and potential royalties, are important parameters that need to be addressed.
  • Software Development: Beyond the hardware, robust, and user-friendly software might be critical for data interpretation and integration into existing healthcare IT ecosystems.
  • Current Practices: An understanding of existing clinical workflows and protocols helps to seamlessly integrate the new biomarkers into routine use.
  • Stakeholder Analysis: From clinicians to administrators, and from payers to patients, understanding the needs and constraints of all stakeholders is crucial.
  • Regulatory Compliance: Compliance with In Vitro Diagnostic Regulation (IVDR) and other applicable guidelines is non-negotiable for market access.
  • Reimbursement Strategy: A thorough analysis of reimbursement models ensures that the technology is not just clinically effective, but also economically viable.
  • Intellectual Property: Protecting the IP associated with the biomarkers is key to commercial viability.
  • Quality Control: Adherence to strict Good Manufacturing Practices (GMP) and ISO 13485 standards is essential to ensure the quality, safety, and efficacy of the biomarkers.

By adopting a holistic view that integrates these elements, researchers can not only significantly enhance the commercial viability of their projects but also contribute to practical improvements in healthcare. In sum, a multiplex biomarker project’s success in clinical settings is contingent on a well-rounded approach that addresses scientific, commercial, and regulatory facets comprehensively.

Scroll to Top